

- 40 -

### CLAIMS

1. Use of a lectin in the manufacture of a medicament for treating a disease or condition resulting from an inhibition or stimulation of C-fibre neuron activity, by modulation of C-fibre neuron activity.

2. Use according to Claim 1 of a lectin which binds to a galactosyl residue.

3. Use according to Claim 1 of a lectin which binds to a glucosyl residue.

4. Use of a nucleic acid sequence encoding the lectin defined in any of Claims 1-3 in the manufacture of medicament for treating a disease or condition resulting from an inhibition or stimulation of C-fibre neuron activity, by modulation of C-fibre neuron activity.

5. Use of a conjugate comprising a first lectin coupled to a peptide or protein wherein said peptide or protein is free of Clostridial neurotoxin enzyme activity, or use of a nucleic acid sequence encoding said conjugate, in the manufacture of a medicament for treating a disease or condition resulting from an inhibition or stimulation of C-fibre neuron activity, by modulation of C-fibre neuron activity.

6. A conjugate comprising a first lectin coupled to a peptide or protein, wherein said first lectin is non-endogenous to humans, and wherein said peptide or protein is free of Clostridial neurotoxin enzyme activity.

7. A conjugate according to Claim 6, wherein said first lectin is non-endogenous to vertebrates.

8. A conjugate according to Claim 6 or Claim 7 wherein the peptide or protein is a second lectin.

9. A conjugate according to Claim 8 wherein the first and second lectins are different.

10. A conjugate according to any of Claims 6-9 wherein the first lectin binds to a galactosyl residue.

- 41 -

11. A conjugate according to any of Claims 6-9 wherein the first lectin binds to a glucosyl residue.
- 5 12. A conjugate according to Claim 9 wherein the first lectin binds to a galactosyl residues and the second lectin binds to a glucosyl residue.
13. A conjugate according to Claim 6 or Claim 7, wherein the peptide or protein is an endopeptidase, or a Clostridial neurotoxin free of enzyme activity.
- 10 14. A conjugate according to any of Claims 6-13 wherein the first lectin and/or the second lectin if present is a lectin derivative, said derivative having been modified to remove a carbohydrate group whilst maintaining the ability of the derivative to bind C-fibres.
- 15 15. A nucleic acid sequence encoding the conjugate of any of Claims 6-13.
16. Use of a conjugate according to any of Claims 6-14, or use of a nucleic acid sequence according to Claim 15, in the manufacture of a medicament for treating a disease or condition resulting from an inhibition or stimulation of C-fibre neuron activity, by modulation of C-fibre activity.
- 20 17. Use according to any of Claims 1-5 or 16 for inhibition of C-fibre activity.
18. Use according to any of Claims 1-5 or 16 for stimulation of C-fibre activity.
- 25 19. Use according to any of Claims 1-5 or 16-18 for treatment of a disease or condition selected from pain, psoriasis, inflammation, mucus hypersecretion, rhinitis, erythema, irritable bowel syndrome, headache, asthma, and arthritis.
- 30 20. A method of treating a disease or condition resulting from an inhibition or stimulation of C-fibre neuron activity, by modulating C-fibre activity, comprising administering an effective amount of a lectin, or a conjugate according to any of Claims 6-14, or a nucleic acid sequence according to Claim 15, to a patient.
- 35 21. A method according to Claim 20 for inhibiting C-fibre activity.
22. A method according to Claim 20 for stimulating C-fibre activity.

- 42 -

23. A method according to any of Claims 20-22 for treating a disease or condition selected from pain, psoriasis, inflammation, mucus hypersecretion, rhinitis, erythema, irritable bowel syndrome, headache, asthma, and arthritis.
- 5 24. A method of preparing a conjugate according to any of Claims 6-14, comprising coupling together, optionally via a linker, the first lectin and the peptide or protein.
- 10 25. A method of preparing a conjugate according to any of Claims 6-14, comprising expressing in a host cell a nucleic acid sequence according to Claim 15, optionally including a linker nucleic acid sequence located within the nucleic acid sequence of Claim 15 to provide a linker molecule between the first lectin and the peptide or protein of the conjugate.
- 15 26. A pharmaceutical composition comprising a lectin and a peptide or protein, wherein the peptide or protein is an endopeptidase or a Clostridial neurotoxin free of enzyme activity.
- 20 27. A pharmaceutical composition according to Claim 26, wherein the peptide or protein is an LH<sub>N</sub> fragment of a Clostridial neurotoxin.
- 25 28. Use of a pharmaceutical composition according to Claim 26 or Claim 27, in the manufacture of a medicament for treating a disease or condition resulting from an inhibition or stimulation of C-fibre neuron activity, by modulation of C-fibre activity.
29. Use according to Claim 28 for treatment of a disease or condition selected from pain, psoriasis, inflammation, mucus hypersecretion, rhinitis, erythema, irritable bowel syndrome, headache, asthma, and arthritis.